Johnson and Johnson 2014 Annual Report Download - page 59

Pre-Tax Profit Identifiable Assets
(Dollars in Millions) 2014(3) 2013(4) 2012(5) 2014 2013 2012
Consumer $1,941 1,973 1,693 $21,813 23,711 24,131
Pharmaceutical 11,696 9,178 6,075 25,803 23,783 23,219
Medical Devices 7,953 5,261 7,187 41,445 44,585 42,926
Total 21,590 16,412 14,955 89,061 92,079 90,276
Less: Expense not allocated to segments(1) 1,027 941 1,180
General corporate(2) 42,058 40,604 31,071
Worldwide total $20,563 15,471 13,775 $131,119 132,683 121,347
Additions to Property,
Plant & Equipment
Depreciation and
Amortization
(Dollars in Millions) 2014 2013 2012 2014 2013 2012
Consumer $581 533 468 $577 539 575
Pharmaceutical 977 856 737 1,053 1,075 1,010
Medical Devices 1,807 1,724 1,230 1,974 2,224 1,857
Segments total 3,365 3,113 2,435 3,604 3,838 3,442
General corporate 349 482 499 291 266 224
Worldwide total $3,714 3,595 2,934 $3,895 4,104 3,666
Sales to Customers Long-Lived Assets(6)
(Dollars in Millions) 2014 2013 2012 2014 2013 2012
United States $34,782 31,910 29,830 $36,835 35,880 35,115
Europe 18,947 18,599 16,945 21,559 24,868 25,261
Western Hemisphere excluding U.S. 7,160 7,421 7,207 3,210 3,281 3,636
Asia-Pacific, Africa 13,442 13,382 13,242 2,438 2,434 2,362
Segments total 74,331 71,312 67,224 64,042 66,463 66,374
General corporate 1,138 992 899
Other non long-lived assets 65,939 65,228 54,074
Worldwide total $74,331 71,312 67,224 $131,119 132,683 121,347
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2014, the Company had one wholesaler distributing products for all three segments that represented
approximately 11.0% of the total consolidated revenues. In 2013 and 2012, the Company did not have a customer that represented
10.0% of total revenues.
(1) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income)
expense. Includes currency related expense of $0.2 billion associated with the acquisition of Synthes, Inc. in 2012.
(2) General corporate includes cash, cash equivalents and marketable securities.
(3) Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices,
Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense,
comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices
segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration
costs of $754 million and $126 million expense for the cost associated with the DePuy ASR™ Hip program. Includes an additional
year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
(4) Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and
Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices
segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the
Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for
the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of
$55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
(5) Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical
Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111
million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes
integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments,
comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments,
respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip
program.
(6) Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097,
respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.
Johnson & Johnson 2014 Annual Report •49